Evidence map›Paper›PMID 33177582›Full record

ArticleScientific reports2020

A novel Trypanosoma cruzi secreted antigen as a potential biomarker of Chagas disease.

Rana Nagarkatti, David Acosta, Nirmallya Acharyya, Fernanda Fortes de Araujo, Silvana Maria Elói-Santos, Olindo Assis Martins-Filho, Andréa Teixeira-Carvalho, Alain Debrabant

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. International journal of molecular sciences · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Rana Nagarkatti *Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA. rana.nagarkatti@fda.hhs.gov.
David Acosta *Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Nirmallya AcharyyaLaboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Fernanda Fortes de AraujoGrupo Integrado de Pesquisas Em Biomarcadores, Instituto René Rachou, Fiocruz-Minas, Belo Horizonte, Brazil.
Silvana Maria Elói-SantosGrupo Integrado de Pesquisas Em Biomarcadores, Instituto René Rachou, Fiocruz-Minas, Belo Horizonte, Brazil.
Olindo Assis Martins-FilhoGrupo Integrado de Pesquisas Em Biomarcadores, Instituto René Rachou, Fiocruz-Minas, Belo Horizonte, Brazil.
Andréa Teixeira-CarvalhoGrupo Integrado de Pesquisas Em Biomarcadores, Instituto René Rachou, Fiocruz-Minas, Belo Horizonte, Brazil.
Alain DebrabantLaboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA. alain.debrabant@fda.hhs.gov.
Center for Biologics Evaluation and Research · USUnited States Food and Drug Administration · USUniversidade Federal de Minas Gerais · BR

Funding

Intramural FDA HHS Intramural grant
6 · The paper itself

Abstract

Chagas drug discovery has been hampered by a lack of validated assays to establish treatment efficacy in pre-clinical animal models and in patients infected with T. cruzi. Reduced levels of parasite secreted antigens in the blood of infected hosts could be used to demonstrate treatment efficacy. A published proteomic study of parasite secreted antigens identified the hypothetical protein Tc_5171 as a secreted antigen. In this report, we developed Tc_5171 specific antibodies and showed that the native protein was expressed by the three life cycle stages of the parasite. Anti-peptide antibodies were able to detect the parasite antigen in blood of infected mice during the acute and the chronic phase of infection. Benznidazole treatment of infected mice significantly reduced their blood antigen levels. Of clinical significance, patients diagnosed with Chagas disease, either asymptomatic or with cardiac clinical symptoms had significantly higher Tc_5171 antigen levels compared to endemic controls. Pair-wise analysis, before and after Benznidazole treatment, of patients with asymptomatic Chagas disease showed a significant reduction in antigen levels post treatment. Taken together, our results indicate that Tc_5171 could be used as a novel biomarker of Chagas disease for diagnosis and to assess treatment efficacy.

Indexed as

AdolescentAdultAgedAnimalsAntibodies, ProtozoanAntigens, ProtozoanBiomarkersChagas DiseaseHumansMacaca mulattaMiceMice, Inbred C3HMice, Inbred C57BLMiddle AgedNitroimidazolesTrypanocidal AgentsAntibodies, ProtozoanAntigens, ProtozoanbenzonidazoleBiomarkersNitroimidazolesTrypanocidal Agents

Identifiers

PMID33177582
PMCPMC7658208
OpenAlexW3104807274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.